SAN DIEGO, Sept. 25, 2013 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced that its management team will present a company overview at the 12th Annual BIO Investor Forum on Tuesday, October 8, 2013 at 4:30 p.m. PT in San Francisco.
A live audio webcast of the presentation will be available on the Investor Relations section of the company's website at http://ir.conatuspharma.com/events.cfm. The replay of the webcast will be available on the company's website within 48 hours after the event.
About Conatus Pharmaceuticals Inc.
Conatus is a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease. Conatus is developing its lead compound, emricasan, for the treatment of patients in orphan populations with chronic liver disease and acute exacerbations of chronic liver disease. Emricasan is a first-in-class, orally active caspase protease inhibitor designed to reduce the activity of enzymes that mediate inflammation and cell death, or apoptosis. Conatus believes that by reducing the activity of these enzymes, emricasan has the potential to interrupt the progression of liver disease. For additional information, please visit www.conatuspharma.com.
CONTACT: Paul Cox, Stern Investor Relations (212) 362-1200, firstname.lastname@example.orgSource:Conatus Pharmaceuticals